A clinical trial listing involving tirzepatide was updated on October 16, 2026. The study, titled "GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial Emulation," was registered under identifier NCT07677865. According to the registry update, the trial status is listed as withdrawn. No phase was specified for this study in the available record. The trial was designed as a target trial emulation examining GLP-1 receptor agonists, a drug class that includes tirzepatide, in relation to Alzheimer's disease. The registry entry does not provide a stated reason for the withdrawal. No results, outcomes, or findings were included in this update, and none should be inferred from the withdrawal status alone. This brief reflects only the status change recorded in the trial registry as of the listed date. Readers interested in the approved uses and regulatory status of tirzepatide can consult the compound overview for additional context.
Tirzepatide Alzheimer's Study "GLP-1 RA and Alzheimer's" Withdrawn
See the full tirzepatide overview
Source: https://clinicaltrials.gov/study/NCT07677865